UCB: FDA approves first naval spray for epilepsy
(CercleFinance.com) - The US Food and Drug Administration has approved UCB's nasal spray to treat intermittent episodes of seizure in people with epilepsy, the Belgian company said on Monday.
The FDA has approved UCB's newest anti-epileptic drug, a benzodiazepine indicated for the acute treatment of seizure clusters and acute repetitive seizures, which are distinct from a patient's usual seizure pattern.
Nayzilam is the first and only FDA-approved nasal option for treating seizure clusters, UCB said.
It is estimated that over 150,000 people in the US with uncontrolled epilepsy also experience seizure clusters.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The FDA has approved UCB's newest anti-epileptic drug, a benzodiazepine indicated for the acute treatment of seizure clusters and acute repetitive seizures, which are distinct from a patient's usual seizure pattern.
Nayzilam is the first and only FDA-approved nasal option for treating seizure clusters, UCB said.
It is estimated that over 150,000 people in the US with uncontrolled epilepsy also experience seizure clusters.
Copyright (c) 2019 CercleFinance.com. All rights reserved.